Clonmel Healthcare

Politician(s) lobbied: Unknown

Intent: Unknown

Methods: Unknown

Politician(s) lobbied: Seán Kelly (MEP), European Parliament

Intent: Highlight the contributions that Clonmel Healthcare has made to the local community and our commitment to supplying affordable medicines in Ireland.

Methods: Event / Reception

Politician(s) lobbied: Unknown

Intent: Unknown

Methods: Unknown

Politician(s) lobbied: Jennifer Carroll MacNeill (Minister), Department of Health

Intent: To arrange a meeting on behalf of Medicines For Ireland (MFI) with the Minister of Health, Jennifer Carol MacNeill to discuss and defer the implementation of the UWWTD in it's current format. MFI believe that this Directive will have a severe negative impact on patient access to critical and essential generic medicines.

Methods: Event / Reception

Politician(s) lobbied: Barry Andrews (MEP), European Parliament; Darragh O'Brien (Minister), Department of Housing, Local Government and Heritage

Intent: Request that our representatives in Europe, encourage the European Council to delay the vote on the recast UWWTD until a full impact assessment can be done, one that accurately estimates the true costs to patients and Europe’s/Ireland’s generic medicine supply. If the vote proceeds, then to request that the implementation of the directive locally in Ireland is reassessed.

Methods: Meeting

Politician(s) lobbied: Darragh O'Brien (TD), Dáil Éireann, the Oireachtas; Stephen Donnelly (TD), Dáil Éireann, the Oireachtas

Intent: To ensure that Irish patients benefit from cost-effective and innovative healthcare solutions. Biosimilar medicines, such as Ustekinumab, offer substantial contributions to healthcare savings. To expedite the use of such biosimilars which are subject to the Framework Agreement on the Supply and Pricing of Medicines 2021. Highlighting Clonmel's Ustekinumab biosimilar with potential savings of at least 55%. Expedite these savings by endorsing biosimilars ahead of the BVB process.::Request that our representatives in Europe, encourage the European Council to delay the vote on the recast UWWTD until a full impact assessment can be done, one that accurately estimates the true costs to patients and Europe’s/Ireland’s generic medicine supply. If the vote proceeds, then to request that the implementation of the directive locally in Ireland is reassessed.

Methods: Meeting